Stem cell patch aims to mend broken hearts in landmark trial

NCT ID NCT07471698

Not yet recruiting Disease control Sponsor: HELP Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether a patch loaded with lab-grown heart muscle cells can help repair damaged heart tissue. Sixteen people with severe heart failure who are already scheduled for bypass surgery will receive either the stem cell patch or a blank patch during their operation. The main goals are to check safety and see if the patch improves heart function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: human induced pluripotent stem cell-derived cardiomyocytes (HiCM-188) loaded onto a chitosan patch
What this could lead to: If it works, this could point toward a way to repair damaged heart muscle and improve heart function in people with severe heart failure.
What could go wrong: This is a very early, small study (16 people) focused on safety. The stem cell patch may not improve heart function, and there are risks like abnormal heart rhythms or tumor formation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CABG-PATIENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CABG-PATIENTS ISCHEMIC HEART FAILURE

Contacts and locations

Locations

The Second Xiangya Hospital of Central South University

Changsha, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.